08 Juin 2026 Ultra-Rapid TDB0206 Injection (BioChaperone Lispro, BCLIS) Improves Postprandial And Daily Glucose Control Vs. Lispro (LIS) In Chinese People With Type 2 Diabetes (T2D) Icon check
Assemblée Générale Mixte du 3 juin 2026
Interview Olivier Soula et Stéphane Boissel – La Bourse et la vie – Mai 2026
Interview Stéphane Boissel – Président du Conseil d’Administration – Mars 2026
Olivier Soula et Mathieu-William Gilbert – Présentation Investir Day Novembre 2025
Interview Olivier Soula – Bourse et Valeurs – Juillet 2025
Assemblée Générale Mixte du 11 juin 2025
Olivier Soula – Bourse et Valeurs, Lyon Pole Bourse 2024
Web Conférence – BioChaperone Combo – Juillet 2024
Interview Olivier Soula – La France de Demain, Radio Classique – Mai 2024
Olivier Soula – LSX World Congress – Avril 2024 (ENG)
Interview Olivier Soula – Le Journal des Biotechs – Mars 2024
BIO-Europe Spring 2024: Interview de Jérémy Benattar
Web Conférence – Résultats financiers du 4ème trimestre 2023
Olivier Soula – Le Revenu TV – Déc. 2023
Web conférence – Diabète : un laboratoire pour le futur de la santé – déc. 2023
Olivier Soula – Investival Showcase (English)
Jérémy Benattar – Investisseur.TV
Olivier Soula – Bourse et Valeurs, Lyon Pole Bourse
11 Juil 2023 EndoC-bH5 cells are storable and ready-to-use human pancreatic beta cells with physiological insulin secretion. Mol Metab. 2023 Jul 11;76:101772 Icon check
Webconférence du 06 juillet 2023
23 Juin 2023 AdoShell® Islets, a new biomaterial for allogenic islet encapsulation, shows 6 months insulin secretion in diabetic immunocompetent rats, Dr. Ouardane Jouannot, June 23, 2023, 83rd scientific Sessions, ADA 2023, San Diego, USA
Résultats Annuels 2022
12 Jan 2023 A co-formulation of pramlintide and insulin A21G (ADO09) improves postprandial glucose and short-term control of mean glucose, time in range, and body weight versus insulin aspart in adults with type 1 diabetes. Diabetes Obes Metab., 2023;25(5):1241-1248. Icon check
Webinaire Investisseurs du 20 sept 2022
Présentation d’AdoShell Islets 2022
27 Juin 2021 ADO09, a coformulation of insulin A21G and pramlintide (Pram), improves blood glucose control and reduces body weight in subjects with T1D, Dr. Grégory Meiffren, June 27, 2021, ADA virtual event.
02 Juin 2021 ADO09, a co-formulation of pramlintide and insulin A21G improves postprandial glucose (PPG) versus insulin Aspart  in type 1 diabetes, Dr.  Grégory Meiffren, June 2, 2021, ATTD, Virtual event.
23 Avr 2021 ADO09, a co‐formulation of the amylin analogue pramlintide and the insulin analogue A21G, lowers postprandial blood glucose versus insulin lispro in type 1 diabetes. Diabetes Obes Metab., 2021;23(4):961-970. Icon check
10 Sep 2020 ADO09, a co-formulation of amylin analog pramlintide and human insulin analog A21G, reduces postprandial blood sugar compared to insulin lispro in type 1 diabetes, Dr.  Grégory Meiffren, September 10, 2020, Société Francophone du Diabète, Virtual Event.
05 Sep 2020 ADO09, A Co-Formulation of the Amylin-Analog Pramlintide and the A21G Human Insulin Analog, Lowers Postprandial Blood Glucose versus Insulin Lispro in Type 1 Diabetes (T1D) presented by Dr. Gregory Meiffren, 2020, ATTD, virtual experience. Icon check
16 Juin 2020 ADO09, a coformulation of pramlintide (PRAM) and insulin A21G, improves postprandial glucose vs. Novolog(R) in Type 1 Diabetes (T1D), Dr. Gregory Meiffren, June 12-16, 2020, ADA virtual experience.
16 Juin 2020 ADO09, a Coformulation of Pramlintide (PRAM) and Insulin A21G, Improves Postprandial Glucose vs. Novolog in Type 1 Diabetes (T1D) (Poster # 2020-LB-7039-Diabetes), presented by Dr. Gregory Meiffren, June 12-16, 2020, ADA virtual experience. Icon check
16 Juin 2020 ADO09, a coformulation of pramlintide (PRAM) and insulin A21G, improves postprandial glucose vs. Novolog(R) in Type 1 Diabetes (T1D), Dr. Gregory Meiffren, June 12-16, 2020, ADA virtual experience.
16 Juin 2020 ADO09, a Coformulation of Pramlintide (PRAM) and Insulin A21G, Improves Postprandial Glucose vs. Novolog in Type 1 Diabetes (T1D) (Poster # 2020-LB-7039-Diabetes), presented by Dr. Gregory Meiffren, June 12-16, 2020, ADA virtual experience. Icon check
03 Juin 2020 ADO09, A Co-Formulation of the Amylin-Analog Pramlintide and the A21G Human Insulin Analog, Lowers Postprandial Blood Glucose versus Insulin Lispro in Type 1 Diabetes (T1D) presented by Dr. Gregory Meiffren, 2020, ATTD, virtual experience. Icon check
21 Fév 2020 “BioChaperone® Combo, A Co-Formulation Of Lispro And Glargine, Improves Postprandial Glucose Control Compared To Lispromix25 Or Lispro And Glargine Injections In Type 2 Diabetes Subjects” (EPO2 E-Poster Viewing), presented by Dr. Grégory Meiffren, February 21, 2019, ATTD, Berlin (Germany) Icon check
10 Juin 2019 “BioChaperone Glucagon Exenatide (BC Glu Exe), a Stable Combination of Glucagon (Glu) and Exenatide (Exe) Achieved Larger Body Weight (BW) Loss than Exe Alone in DIO Mice” (Poster), Author Dr. Martin Gaudier, June 10, 2019, ADA, San Francisco (USA) Icon check
09 Juin 2019 BioChaperone pramlintide insulin (BCPramIns), a new co-formulation of pramlintide (pram) and human insulin (ins), improves post-prandial blood glucose versus both separate injections of pram+ins and insulin lispro (lis) in subjects with T1D”, Dr. Grégory Meiffren, June 9th, 2019, ADA, San Francisco (USA)
09 Juin 2019 BioChaperone pramlintide insulin (BCPramIns), a new co-formulation of pramlintide (pram) and human insulin (ins), improves post-prandial blood glucose versus both separate injections of pram+ins and insulin lispro (lis) in subjects with T1D”, Dr. Grégory Meiffren, June 9th, 2019, ADA, San Francisco (USA)
15 Avr 2019 Article : Grégory Meiffren PhD, Theresa Herbrand MD, Ernestos Anastassiadis MD, Oliver Klein MD, J. Hans DeVries MD, Tim Heise MD, Bertrand Alluis PhD, Claire Mégret PhD, Martin Gaudier PhD, Olivier Soula PhD, Leona Plum‐Mörschel MD.
“Better glycemic control with BioChaperone® Combo (BC Combo) than with insulin lispro Mix25 (LMix) or separate glargine & lispro (G+L) administrations after a test meal in subjects with type 2 diabetes (T2DM)”
Diabetes Obes Metab., 2019;21(7):15701575. Icon check
08 Avr 2019 Better glycaemic control with BioChaperone glargine lispro co-formulation than with insulin lispro Mix25 or separate glargine and lispro administrations after a test meal in people with type 2 diabetes. Diabetes Obes Metab., 2019;21(7):15701575. Icon check
Rejoignez notre liste de diffusion. S'abonner